BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
BioCryst (Nasdaq: BCRX) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst (Nasdaq: BCRX) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 1:30 p.m. ET.
A live audio webcast and replay will be available in the Investors & Media section of BioCryst’s website at www.biocryst.com.
Details
News Market Reaction – BCRX
On Jan 6, the day this news came out, BCRX closed 2.29% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference edition
- 44th annual
- J.P. Morgan Healthcare Conference
- Presentation time
- 1:30 p.m. ET
- BioCryst presentation on Jan 12, 2026
Historical Context
-
FDA approval of ORLADEYO oral pellets for pediatric HAE patients.
-
Inducement stock options and RSUs granted to new employees.
-
Early termination of HSR waiting period for Astria acquisition.
-
Astria Q3 results plus detailed BioCryst cash-and-stock deal terms.
-
APeX-P interim data showing sustained ORLADEYO attack reduction in children.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 1:30 p.m. ET.
A link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.